ReviewCanadian family physician Medecin de famille canadien2026
Psychedelic-assisted psychotherapy: Emerging paradigm.
Review in Canadian family physician Medecin de famille canadien, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review psychedelic-assisted psychotherapy (PAP), including its principles, mechanisms of action, safety considerations, and current state of evidence relevant to Canadian primary care. SOURCES OF INFORMATION: The evidence of PAP is evolving and is primarily derived from phase 2 and 3 clinical trials in specialized research settings. Systematic reviews and meta-analyses suggest potential benefit for selected conditions, though heterogeneity is high, and long-term comparative effectiveness relative to standard treatments remains uncertain. MAIN MESSAGE: PAP combines structured psychotherapy with supervised administration of psychedelic medicines in controlled settings. While not a first-line treatment or a primary care-delivered intervention, family physicians may encounter patients seeking information, referral, or guidance regarding PAP and should be familiar with basic evidence, contraindications, access pathways, and harm-reduction considerations.
conclusionPAP represents an emerging intervention with potential clinical relevance for select patients. As research and regulatory frameworks continue to evolve in Canada, cautious, evidence-informed engagement by family physicians is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.